# Embody
# LLM discovery file
# Generated 2026-04-18T03:09:48.076Z

> Embody is a GLP-1 program information site focused on semaglutide, tirzepatide, provider review, and the path from intake to delivery.

## Important Notice
Medical eligibility, diagnosis, prescribing, and treatment decisions are made by licensed healthcare providers after review of the intake and any required follow-up.

## Key Pages
- [Home](https://tryjoinem.com/)
- [Solutions](https://tryjoinem.com/solutions)
- [Topic Hubs](https://tryjoinem.com/hub)
- [Methodology](https://tryjoinem.com/methodology)
- [Editorial Policy](https://tryjoinem.com/editorial-policy)
- [Evidence Review Policy](https://tryjoinem.com/medical-review-policy)
- [Evidence Review Team](https://tryjoinem.com/medical-reviewers)
- [Authors](https://tryjoinem.com/authors)
- [About](https://tryjoinem.com/about)
- [Privacy Policy](https://tryjoinem.com/privacy)
- [Terms of Service](https://tryjoinem.com/terms)

## Solutions
- [Semaglutide GLP-1 Injections](https://tryjoinem.com/solutions/semaglutide-access)
- [Tirzepatide GLP-1 / GIP Injections](https://tryjoinem.com/solutions/tirzepatide-access)

## Topic Hubs
- [How Embody Works](https://tryjoinem.com/hub/how-glp1-access-works)
- [Semaglutide vs Tirzepatide](https://tryjoinem.com/hub/medication-pathways)
- [Cost, Support, and Eligibility](https://tryjoinem.com/hub/cost-eligibility-and-safety)

## Profiles
- [Embody Editorial Team](https://tryjoinem.com/authors/embody-editorial-team)
- [Embody Evidence Review Team](https://tryjoinem.com/medical-reviewers/embody-evidence-review-team)

## Crawl and Index Signals
- [Sitemap](https://tryjoinem.com/sitemap.xml)